BEYOND AIR INC (XAIR)
NASDAQHealth CareMedical - DevicesSnapshot 2026-09-04
$3.53-1.67%
Close 2026-09-04 · 1-day change
NASDAQHealth CareMedical - DevicesSnapshot 2026-09-04
QuarterlyIQ Insights · XAIR
How strong the business is — where it ranks within its sector on capital efficiency and cash generation, and how well management has been executing.
How management runs the business: capital, margins, balance sheet, and how reliably they guide and deliver.
A guidance track record builds as the company issues and delivers on guidance.
Priorities management has stated in recent disclosures, with status and evidence drawn from earnings calls, filings, and press releases.
Execute commercial launch of second-generation LungFit PH system pending FDA approval and expand market adoption domestically and internationally.
Stated as a priority in 2 of last 2 quarters. Management reaffirmed 2026 revenue guidance of $8 million excluding second-generation LungFit PH and 2027 guidance of $16-$18 million including it, implying more than 110% growth. The company is preparing for commercial launch pending FDA approval, showing delivering trajectory toward expanded market adoption.
Each factor is a parallel diagnostic with a clear read of what it shows and how names like it have historically fared. Never aggregated into a single score.
Operating income rose in 2 of the last 3 quarter-over-quarter moves. Historically, Health Care names rated neutral grew net income 51% of the time over the next year (vs 41% for the rest of the cohort, n=13363).
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
“We believe these efforts position us well for the anticipated launch of our second-generation LungFit PH system, pending FDA approval.”
“We are encouraged by the market interest in the second-generation LungFit PH system, which is currently under FDA review.”
Grow LungFit PH adoption by expanding U.S. group purchasing agreements and international distribution network to increase hospital and health system reach.
Stated in 2 of last 2 quarters. Management reported expansion of U.S. market access via a third major group purchasing agreement covering nearly 2,000 hospitals and international distribution now spanning over 45 countries. This reflects delivering progress in expanding LungFit PH market access.
“Entered into a national group purchasing agreement with a leading U.S. group purchasing organization, expanding reach by nearly 2,000 U.S. hospitals.”
“Expanded the global distribution network for LungFit PH throughout fiscal year 2026, now covering more than 45 countries.”
Secure FDA approval for the PMA supplement of the second-generation LungFit PH system to enable commercial launch and expanded labeling.
Stated in 2 of last 2 quarters. Management confirmed FDA review of the PMA supplement submitted in June 2025 with approval expected in second half of 2026. The regulatory milestone remains pending, consistent with management's prior statements.
“PMA supplement for second-generation LungFit PH system under FDA review; approval expected in 2H CY2026.”
“Awaiting approval of the PMA supplement for the second-generation LungFit PH, submitted to the U.S. FDA in June 2025.”
Raise capital via private placement to support commercial launch and general corporate purposes, including up to $30.1 million in gross proceeds.
Newly stated in 2026-Q3 (private placement announced July 2026). The company secured a private placement expected to raise up to $30.1 million to support the commercial launch of second-generation LungFit PH and general corporate purposes. This financing aligns with management's capital allocation priorities.
Regain compliance with Nasdaq minimum bid price requirement by implementing a reverse stock split approved by stockholders.
Stated in 2 quarters including 2026-Q2 and earlier. Management disclosed Nasdaq granted continued listing subject to regaining compliance with minimum bid price by July 31, 2026, with a reverse stock split approved by stockholders to achieve this. The priority remains active with mixed progress.
“Nasdaq granted the Companys request to continue listing, subject to regaining compliance by July 31, 2026.”
Over the trailing year it converted 0.80x of net income into operating cash flow.
Not enough signal yet.
Not enough signal to read sensitivity to the US dollar, the broad stock market, Fed net liquidity, real (inflation-adjusted) rates, long-term interest rates (low R² over the window).
31 material management or governance events in the past 24 months, led by capital-allocation actions. Historically, Health Care names rated volatile grew net income 53% of the time over the next year (vs 50% for the rest of the cohort, n=3986).
Not investment advice. As of 2026-09-04.